The U.S. Food and Drug Administration (FDA) recently approved a groundbreaking new option for preventing HIV, the virus that causes AIDS. The injectable drug lenacapavir was approved in June and is ...

Pill burden decreases and antiretroviral regimens simplify for many of the participants who start lenacapavir.

– European Commission Grants Marketing Authorization for Sunlenca, Helping to Address a Critical Unmet Clinical Need for People with Multi-Drug-Resistant HIV Who Have Very Limited Treatment Choices – ...

The U.S. and Eswatini have entered a five-year health cooperation agreement involving a $242 million understanding to enhance ...

A newly approved drug gives almost total protection against getting HIV. The FDA approved lenacapavir last week. Patients need just two injections of it a year to get that protection, but as NPR's ...

The first deliveries of lenacapavir to the African continent represent a turning point in the fight against HIV.

Please provide your email address to receive an email when new articles are posted on . Twice-yearly lenacapavir injections reduced HIV infections by 96% in a phase 3 trial. Gilead Sciences will begin ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

Advocacy groups state that Indian generic manufacturers are positioned to supply lenacapavir at affordable prices, but regulatory delays and Gilead’s patent filings threaten to affect access globally.

Mashatile urges South Africa to avoid past ARV-era mistakes as the country rolls out Lenacapavir, a breakthrough twice-yearly ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has declined the proposal ...

The U.S. and Eswatini signed a five-year health cooperation agreement on Friday, the State Department said, as the Trump administration continues its global health plan to provide aid while requiring ...